3 years of historical data (2022–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Pelthos Therapeutics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Market Cap | $85M | — | — | — |
| Enterprise Value | $87M | — | — | — |
| P/E Ratio → | -1.95 | — | — | — |
| P/S Ratio | — | — | — | — |
| P/B Ratio | — | — | — | — |
| P/FCF | — | — | — | — |
| P/OCF | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| EV / Revenue | — | — | — | — |
| EV / EBITDA | — | — | — | — |
| EV / EBIT | — | — | — | — |
| EV / FCF | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Gross Margin | — | — | — | — |
| Operating Margin | — | — | — | — |
| Net Profit Margin | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ROE | — | — | — | — |
| ROA | -1085.7% | -1085.7% | -9745.9% | -4464.2% |
| ROIC | — | — | — | — |
| ROCE | — | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $2M ($2M total debt minus $513443 cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Debt / Equity | — | — | — | — |
| Debt / EBITDA | — | — | — | — |
| Net Debt / Equity | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — |
| Debt / FCF | — | — | — | — |
| Interest Coverage | -9.63 | -9.63 | -13.23 | -16.51 |
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.34x is below 1.0, meaning current liabilities exceed current assets. The current ratio has improved from 0.01x to 0.34x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Current Ratio | 0.34 | 0.34 | 0.01 | 0.01 |
| Quick Ratio | 0.34 | 0.34 | 0.01 | 0.01 |
| Cash Ratio | 0.13 | 0.13 | 0.01 | 0.01 |
| Asset Turnover | — | — | — | — |
| Inventory Turnover | — | — | — | — |
| Days Sales Outstanding | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Pelthos Therapeutics Inc. returns 0.2% to shareholders annually primarily through share buybacks.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Dividend Yield | — | — | — | — |
| Payout Ratio | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Earnings Yield | — | — | — | — |
| FCF Yield | — | — | — | — |
| Buyback Yield | 0.2% | — | — | — |
| Total Shareholder Yield | 0.2% | — | — | — |
| Shares Outstanding | — | $587620 | $576752 | $576752 |
Compare PTHS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| PTHSYou | $85M | -1.9 | — | — | — | — | — | — | — |
| UTHR | $22B | 18.1 | 12.9 | 21.1 | 87.9% | 46.9% | 19.7% | 21.1% | — |
| ZLAB | $21B | -12.0 | — | — | 58.6% | -49.9% | -22.6% | -42.8% | — |
| AMRN | $6B | -3.5 | — | — | 35.6% | -40.2% | -15.8% | -18.7% | — |
| ALKS | $5B | 21.0 | 15.9 | 9571.4 | 86.3% | 17.2% | 14.7% | 14.9% | 0.2 |
| ADMA | $4B | 19.2 | 25.1 | 33.7 | 51.5% | 32.6% | 81.6% | 37.7% | 0.6 |
| ARQT | $3B | -207.5 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
| LQDA | $3B | -18.7 | — | — | 58.0% | -866.6% | -209.4% | -500.7% | — |
| SLGL | $3B | -241.3 | — | — | 98.0% | -104.1% | -31.4% | -41.5% | — |
| MLYS | $2B | -8.0 | — | — | — | — | -82.2% | -107.3% | — |
| ARDX | $2B | -25.2 | — | — | 90.3% | -10.1% | -36.2% | -10.8% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 3 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how PTHS stacks up against sector leader United Therapeutics Corporation.
Start ComparisonPelthos Therapeutics Inc.'s current P/E ratio is -1.9x. This places it at the 50th percentile of its historical range.
Based on historical data, Pelthos Therapeutics Inc. is trading at a P/E of -1.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.